Transcatheter Aortic Valve Replacement (TAVR)
Transcatheter Aortic Valve Replacement Approval
FDA approves TAVR for patients with severe symptomatic aortic stenosis
Read more to see if you qualify for TAVR
What is Transcatheter Aortic Valve Replacement (TAVR)?
One of the most promising procedures for select patients with severe symptomatic aortic stenosis (narrowing of the aortic valve opening) is Transcatheter Aortic Valve Replacement (TAVR). TAVR allows doctors to implant a device into a heart valve without open surgery.
How is Transcatheter Aortic Valve Replacement (TAVR) Performed?
During TAVR, surgeons insert a catheter into a blood vessel through a small incision in the patient's leg. They then guide it to the heart, where they carefully position the device in the valve and retract the catheter.
The patient remains under general anesthesia throughout the procedure and may be discharged from the hospital within 48 hours. There is no surgical wound beyond the small puncture mark where surgeons inserted the catheter. After the procedure, this is covered with a small adhesive strip.
NewYork-Presbyterian physicians were the principal investigators of the national clinical trials establishing the effectiveness of this minimally invasive procedure.
Do I Qualify for Transcatheter Aortic Valve Replacement (TAVR)?
Having a heart valve replacement can be scary. Fortunately, TAVR, a less invasive procedure, is a viable option for more patients than ever before. Initially approved for patients age 60 and older who were considered high risk for complications from open-heart surgery, the US Food and Drug Administration has recently cleared the use of TAVR in patients with severe symptomatic aortic stenosis who are low risk for surgical intervention, sparing them from open-heart surgery. This change means more people living with severe aortic stenosis may now be candidates for the procedure.
In national clinical trials led by NewYork-Presbyterian physicians, TAVR was found to be at least as effective as and sometimes superior to surgery for patients who are younger (age 60+) and more active than the high-risk patients for which TAVR was originally created. Patients who underwent TAVR had shorter lengths of hospital stays, lower mortality rates, and higher blood flow performance.
Transcatheter Aortic Valve Replacement (TAVR) at NewYork-Presbyterian
Transcatheter Aortic Valve Replacement (TAVR) has progressed dramatically in terms of device technologies and patient selection due, in large part, to the transformative work of interventional cardiologists and cardiac surgeons at NewYork-Presbyterian.
Our physicians have served and continue to serve as principal investigators in landmark trials related to transcatheter valve therapies, including multicenter studies for aortic and mitral valve disease, and now tricuspid valve disease.
NewYork-Presbyterian’s cardiac specialists are currently performing more than 500 Transcatheter Aortic Valve Replacement (TAVR) cases per year. 70% of our patients are discharged in two days or less.
Experts in Transcatheter Aortic Valve Replacement (TAVR)
NewYork-Presbyterian/Columbia University Irving Medical Center
NewYork-Presbyterian/Weill Cornell Medical Center
William Acquavella Heart Valve Center